Bloomberg Data License provides billions of data points daily spanning Reference, ESG, Pricing, Risk, Regulation, Fundamentals, Estimates, Historical data and more to help you streamline ...

Beam Therapeutics Inc. has announced that it will present updated safety and efficacy data from 17 patients involved in the ongoing BEACON Phase 1/2 clinical trial of BEAM-101, a gene therapy for ...

To associate your repository with the arb-beam-software-for-data-synchronization topic, visit your repo's landing page and select "manage topics." Learn more Footer ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...

BEAM-302 showed 91% corrected M-AAT and 79% drop in mutant Z-AAT at Day 28 in the 60 mg dose cohort. Beam to enroll 75 mg dose cohort and dose first liver disease patient in 2H 2025. Get the ...

Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 ...

Beam Therapeutics’ first clinical data in the rare disease alpha-1 antitrypsin deficiency “set a bar for efficacy in the space,” according to one analyst. But the ongoing market slide poses ...

BEAM-101 Phase 1/2 trial data showed HbF levels exceeded 60%, HbS dropped below 40%, with normalized hemolysis markers. Preclinical BEAM-103 results indicated rapid HbF induction and long-term ...

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch. Nov. 07, 2024 2:25 PM ET Beam Therapeutics Inc. (BEAM) Stock BEAM 3 Comments 1 Like. Terry Chrisomalis.

Initial data as of a June 11, 2024, data cut in 3 patients treated with BEAM-201 show a safety profile consistent with underlying disease, lymphodepletion and AEs associated with CAR-T therapy.